STRO — SUTRO BIOPHARMA, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1382101 ·
Last close
$15.32
Market Cap
$254.02M
52W High
$43.85
52W Low
$7.15
ADV30
290,463
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 9,839,000 | — | -29,687,000 | -38,533,000 | 194,462,000 | 54,335,000 | 297,779,000 |
| Mar 2026 | 14,523,000 | — | -29,614,000 | -38,484,000 | 241,988,000 | 73,682,000 | 308,875,000 |
| Dec 2025 | 11,647,000 | — | -33,657,000 | -46,762,000 | 173,830,000 | 58,130,000 | 306,282,000 |
| Sep 2025 | 9,693,000 | — | -38,901,000 | -56,857,000 | 209,658,000 | 65,927,000 | 296,926,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-151,607,000
Investing CF
$16,007,000
Financing CF
$103,053,000
CapEx
$-532,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-20.12
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,016,439,000
Inventory
—
Receivables
$12,484,000
ST Investments
$128,876,000
EBIT TTM
$-111,812,000
Pretax Income TTM
$-153,717,000
Interest Exp TTM
$41,905,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$45,702,000
EBITDA
$-125,795,000
Free Cash Flow
$-100,756,000
Enterprise Value
$125,995,544
Total Cash
$164,346,000
Total Debt
$10,783,000
Shares Out
16,581,171
Trailing EPS
$-17.37
Book Value
$-6.23
ROE
—
ROA
-36.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 102,484,000 | -104,952,000 | -191,086,000 | 173,830,000 | 306,282,000 | -132,452,000 | -177,231,000 |
| Dec 2024 | 62,043,000 | -238,453,000 | -227,461,000 | 387,207,000 | 342,606,000 | 44,601,000 | -191,540,000 |
| Dec 2023 | 153,731,000 | -89,278,000 | -106,793,000 | 470,736,000 | 321,087,000 | 149,649,000 | -111,616,000 |
| Dec 2022 | 67,772,000 | -128,943,000 | -119,204,000 | 406,944,000 | 189,896,000 | 217,048,000 | 3,549,000 |
TTM Snapshot
Revenues TTM
$99,608,000
NetIncome TTM
$-153,602,000
OpCashFlow TTM
—
Assets (Latest)
$241,988,000
Forward EPS
$-6.21
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $14.88 · call volume: 4 · put volume: 11Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FATE | FATE THERAPEUTICS INC | $255.22M | $2.13 | — |
| PALI | PALISADE BIO, INC. | $252.69M | $1.45 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $260.49M | $1.03 | — |
| SABS | SAB Biotherapeutics, Inc. | $262.95M | $2.89 | — |
| LXEO | Lexeo Therapeutics, Inc. | $263.37M | $3.21 | — |
News headlines (Yahoo Finance, 1h cache)
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
2026-09-29 12:00 · Yahoo
STRO Stock Plummets 15% — What Drove The Selloff?
2026-08-12 20:07 · Yahoo
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
2026-08-12 11:00 · Yahoo
News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts
2026-05-28 11:19 · Yahoo
US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results
2026-05-17 13:02 · Yahoo
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-14 20:05 · Yahoo
Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now
2026-04-29 17:00 · Yahoo
Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead Program
2026-05-01 08:17 · Yahoo
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
2026-04-19 23:45 · Yahoo
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
2026-08-11 12:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.